MiNK Therapeutics (INKT) Expected to Release Earnings on Thursday

MiNK Therapeutics (NASDAQ:INKT) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Friday, May 15th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. On average, analysts expect MiNK Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MiNK Therapeutics Trading Up 2.5%

NASDAQ:INKT opened at $11.22 on Wednesday. MiNK Therapeutics has a twelve month low of $8.48 and a twelve month high of $18.17. The company has a market cap of $55.90 million, a PE ratio of -3.95 and a beta of 0.48. The company’s 50 day moving average is $11.40 and its two-hundred day moving average is $11.25.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on INKT shares. Weiss Ratings raised shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Zacks Research upgraded MiNK Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of MiNK Therapeutics in a research report on Monday, May 18th. Finally, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MiNK Therapeutics has an average rating of “Moderate Buy” and an average price target of $35.00.

Institutional Trading of MiNK Therapeutics

A hedge fund recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.